Gilotrif (afatinib; Boehringer Ingelheim) Drug Profile and Overview 2019 - ResearchAndMarkets.com

DUBLIN--()--The "Gilotrif" drug pipelines has been added to ResearchAndMarkets.com's offering.

Gilotrif (afatinib; Boehringer Ingelheim) is an orally administered tyrosine kinase inhibitor (TKI) that irreversibly binds to epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 1 (HER1), HER2, and HER4.

In cancerous cells where EGFR and HER2 receptors are overexpressed, activation of these receptors can trigger cell-signaling pathways that lead to uncontrolled tumor cell proliferation. Gilotrif works by blocking these receptors, preventing their activation and thereby inhibiting the unwanted signaling pathways. Gilotrif irreversibly binds to two key receptors involved in cell proliferation, in comparison to first-generation TKIs which only provide single reversible receptor blocking.

Key Topics Covered:

OVERVIEW

  • Drug Overview
  • Product Profiles
  • Gilotrif: Non-small cell lung cancer (NSCLC)
  • Gilotrif: Head and neck cancer

LIST OF FIGURES

  • Cemiplimab for non-small cell lung cancer - SWOT analysis
  • The authors drug assessment summary for cemiplimab in non-small cell lung cancer
  • The authors drug assessment summary for cemiplimab in non-small cell lung cancer
  • Dacomitinib for non-small cell lung cancer - SWOT analysis
  • The authors drug assessment summary for dacomitinib in non-small cell lung cancer
  • The authors drug assessment summary of Gilotrif for SCCHN
  • Dacomitinib sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26

LIST OF TABLES

  • Capmatinib patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
  • Gilotrif late-phase trial data in non-small cell lung cancer
  • Gilotrif sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Gilotrif patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
  • Dacomitinib pivotal trial data in non-small cell lung cancer
  • Gilotrif Phase III trial data in head and neck cancer
  • Gilotrif early-phase data in head and neck cancer
  • Gilotrif patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/crr95w

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Lung Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Lung Cancer Drugs